Current Report Filing (8-k)
30 January 2019 - 9:07AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported): January 29, 2019
OWC
PHARMACEUTICAL RESEARCH CORP.
(Exact Name of Registrant as Specified in its Charter)
Commission
File No.: 0-54856
Delaware
|
|
98-0573566
|
(State
of Incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
2
Ben Gurion Street, Ramat Gan, Israel
|
|
5257334
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
Telephone Number, including area code: 972 (72) 2608004
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01 Other Events.
OWC
PHARMACEUTICAL RESEARCH CORP. REPORTS POSITIVE SAFETY DATA FROM
PHASE
1 (SAFETY) CLINCIAL TRIAL FOR MEDICAL GRADE CANNABIS OINTMENT FOR TREATMENT OF SKIN DISEASES
Ramat
Gan, Israel, January 29, 2019 –OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies
targeting a variety of different medical conditions and disorders, today reported positive Phase 1 safety data for its medical
grade cannabis MSG ointment for the treatment of skin diseases. No severe adverse events were observed in the trial. The Company
is on track to initiate a Phase 2 trial of MSG ointment for the treatment of psoriasis during the third quarter 2019.
This
Phase 1 trial was a single center, prospective, placebo-controlled, study to assess the safety and tolerability of topical MGC
ointment (3% CBD, 3% THC) in healthy subjects. The study was conducted at Sheba Academic Medical Center in Israel between September
2017 when the first subject entered the study and January 2019 when the last subjected completed the study.
The
Study was divided into two stages:
Stage
I was designed to evaluate the safety and tolerability following a single dose application of MGC ointment in 26 healthy volunteers.
Subjects were hospitalized and monitored for 24 hours. Stage 2 was designed to assess the safety and tolerability of repeated
applications of MGC topical ointment in healthy volunteers over a six week period. A total of 20 healthy subjects (13 subjects
that participated in stage I and 7 newly recruited subjects) participated in this stage. MSG ointment treatment was applied by
the subjects themselves, at home, twice daily. Subjects were asked to apply MGC ointment (daily dose of 30 mg CBD: 30 mg THC)
on one arm and a placebo ointment (vehicle only) on the other arm. Investigators were blinded as to the type of treatment that
was applied to each arm.
No
severe adverse events were observed in either stages of the study. Minor irritation was observed in one subject.
About
OWC Pharmaceutical Research Corp
OWC
Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively ‘OWC’
or the ‘Company’) conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments
for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.
OWCP
is also developing unique and effective delivery systems and dosage forms of medical cannabis. All OWC research is conducted at
leading Israeli hospitals and scientific institutions and led by internationally renowned investigators.
Contact:
Mordechai Bignitz , Chief Executive Officer - OWC Pharmaceutical research crop,
info@owcpharma.com
Tel:
+972-(72)-260-8004
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
OWC
Pharmaceutical Research Corp.
|
|
|
|
|
By:
|
/s/
Mordechai Bignitz
|
|
Name:
|
Mordechai
Bignitz
|
|
Title:
|
Chief
Executive Officer
|
|
|
|
Date:
January 29, 2019
|
|
|
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Apr 2024 to May 2024
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about OWC Pharmaceuticals Research Corporation (CE) (OTCMarkets): 0 recent articles
More Owc Pharmaceutical Research Corp. News Articles